Winter Park, Florida--(Newsfile Corp. - October 20, 2026) - Adia Med, Inc. (OTCQB: ADIA) today announced that its Chief Executive Officer, Larry Powalisz, purchased a 7% economic interest in Adia Labs LLC for $350,000 in cash. Under the completed Membership Interest Purchase Agreement, Powalisz purchased seven membership units at $50,000 per unit.

Full repayment eliminates the Company's unsecured revolving credit facility and simplifies its remaining obligations Winter Park, Florida--(Newsfile Corp. - October 13, 2026) - Adia Med, Inc. (OTCQB: ADIA) (the "Company") today announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer. Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/318700_adiamed.jpg Financial Highlights $934,970.94 repaid in total, including all outstanding principal and accrued interest.

Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC to Live Oak Health, a stem cell distributor doing business as QCM Biologics, for $1.5 million, and that the sale is paired with a distribution partnership. The Company has filed a Form 8-K related to the transaction.

New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies. Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new research-use offerings: Adia30M, AdiaClear, and AdiaEXO.

Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand. Management estimates that Adia Labs' biologic inventory had a retail value of approximately $380,000 at the end of the second quarter of 2026.

Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes: At least 300 round-lot holders; A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and Adia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.

Company converts campus session at Full Sail University into an intern-led content team across YouTube, Meta, TikTok, X, and LinkedIn Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing. From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/311967_adiamedimage.jpg The session introduced Adia Med's mission, research pipeline, and growth story to a room full of creative talent and opened the door to hands-on collaboration in content, social media, and digital marketing.

Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market. Lucosky Brookman LLP To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), conducting necessary due diligence related to the registration statement, preparation and filing of responses to SEC comments and any related amendments, preparation and filing of the Company's application for listing of its securities on a nationally recognized securities exchange (including responses to comments and amendments), and assisting with general corporate matters related to the registration statement and listing application.